[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoxia-ischemia-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoxia-ischemia-brain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,74,87,110,143,171,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100054239","pediatric-influence-of-cooling-duration-on-efficacy-in-cardiac-arrest-patients-p-icecap-100054239",false,"NCT05376267","Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)","Inclusion criteria:\n\n* Age 2 days to \\\u003C 18 years with corrected gestational age of at least 38 weeks\n* Chest compressions for at least 2 minutes\n* Coma or encephalopathy after resuscitation from Out-of-Hospital Cardiac Arrest (OHCA)\n* Requires continuous mechanical ventilation through endotracheal tube or tracheostomy\n* Definitive temperature control device initiated\n* Randomization within 6 hours of Return of Spontaneous Circulation (ROSC)\n* Informed consent from Legally Authorized Representative (LAR) including intent to maintain life support for 120 hours\n\nExclusion criteria:\n\n* Glasgow Coma Motor Score (GCMS) = 6\n* LAR does not speak English or Spanish\n* Duration of Cardiopulmonary Resuscitation (CPR) \\> 60 minutes\n* Severe hemodynamic instability with continuous infusion of epinephrine or norepinephrine of 2 micrograms per kilogram per minute (μg\u002Fkg\u002Fminute) or initiation of Extracorporeal membrane oxygenation (ECMO)\n* Pre-existing severe neurodevelopmental deficits with Pediatric Cerebral Performance Category (PCPC) =5 or progressive degenerative encephalopathy\n* Pre-existing terminal illness, unlikely to survive to one year\n* Cardiac arrest associated with brain, thoracic, or abdominal trauma\n* Active and refractory severe bleeding prior to randomization\n* Extensive burns or skin lesions incompatible with surface cooling\n* Planned early withdrawal of life support before 120 hours\n* Sickle cell anemia\n* Pre-existing cryoglobulinemia\n* Non-fatal drowning in ice covered water\n* Central nervous system tumor with ongoing chemotherapy\n* Previous enrollment in P-ICECAP trial\n* Prisoner\n* Chronic hypothermia\n* New post-cardiac arrest diabetes insipidus\n* Pregnancy","ALL","2 Days","17 Years",{"count":19,"type":20},900,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.\n\nThe study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.",[26,27,28],"Cardiac Arrest, Out-Of-Hospital","Hypothermia, Induced","Hypoxia-Ischemia, Brain",[30,31,32,33],"Bayesian Adaptive Clinical Trial","Hypothermia, therapeutic","Coma","Pediatric","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2022-08-05",{"date":42,"type":20},"2028-03-31",{"name":44,"class":45},"University of Michigan","OTHER",62,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":17,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100552185","ecmo-abi-detection-with-hyperfine-100552185","NCT06469801","ECMO ABI Detection With Hyperfine","Low-Field Bedside MRI for Detection of Acute Brain Injury in Pediatric Extracorporeal Membrane Oxygenation","Inclusion Criteria\n\n* Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit\n* Ages 0-17 years\n* Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO\n\n  • High risk participants include, but are not limited to:\n* Undergoing cardiac surgery\n* Congenital heart disease\n* Congenital diaphragmatic hernia\n* Refractory hypoxemic and\u002For hypercarbic respiratory failure\n* Vasoactive-refractory shock\n\nExclusion Criteria\n\n* Pregnancy\n* Active implants such as:\n\n  * Pacemaker\n  * Implanted defibrillator\n  * Implanted insulin pump\n  * Deep brain stimulator\n  * Vagus nerve stimulator\n  * Cochlear implant\n  * Programmable shunt\n* MRI incompatible surgical hardware (e.g., staples, screws, etc.)\n* Metal-containing tattoos or permanent make-up on head or neck\n* Suspected metal in eye, e.g.,\n* Former or current welders, metal workers, or individuals with a metal injury\n* Metal shrapnel\n* Passive implants are considered MRI-conditional","0 Days",{"count":56,"type":20},30,[23],"The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.",[60,61,28,62],"Acute Brain Injury","Extracorporeal Membrane Oxygenation Complication","Stroke, Acute",[33],"2026-06-30",{"date":66,"type":38},"2026-07-01",{"date":68,"type":38},"2024-07-23",{"date":70,"type":20},"2027-12-01",{"name":72,"class":45},"Children's Mercy Hospital Kansas City",1,{"id":75,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":24,"conditions":78,"keywords":79,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":85,"locationsCount":86},"100468168",{"count":19,"type":20},[23],[26,27,28],[30,31,32,33],"2026-06-03",{"date":82,"type":38},"2026-06-05",{"date":40,"type":38},{"date":42,"type":20},{"name":44,"class":45},61,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":73},"100377765","predictors-for-survival-and-good-neurological-outcome-in-e-cpr-and-non-cpr-treated-patients-100377765","NCT04198792","Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients","Inclusion Criteria:\n\n* ECMO-treated patients.\n\nExclusion Criteria:\n\n* None","16 Years",{"count":95,"type":20},700,"OBSERVATIONAL","In ECPR, where CPR times often range from 30 to 120 minutes, only patients with good circulation during CPR survive, while non-survivors commonly suffer from anoxic brain injury. The selection process during CPR is challenging causing a general survival rate of just 2 out of 10, and the urgent need for better selection criteria has been emphasized. It it crucial to keep cardiac arrest times as short as possible, pre primed-ECMO can facilitate this.\n\nThe ECMO treatment and the long CPR times of ECPR can also affect the measurements of the neurologic prognostication guidelines after cardiac arrest, making its validity uncertain in this specific cohort. Further, the long-term neuropsychological follow-up is limited to a few patients, making it uncertain if ECPR gives the survivors good long-term life satisfaction or just a prolonged life.\n\nOur overall aim is to optimize and improve the care pathway for ECPR patients by refining patient selection, assessing pre-primed ECMO, validating neurological prognostication guidelines, and understanding long-term outcomes and challenges faced by survivors.\n\nSpecific Aim 1: Evaluating predictors for good neurological outcomes in ECPR and to develop and validate (internally and externally) an evidence-based selection tool for ECPR.\n\nSpecific aim 2: To assess the sterility and function of pre-primed ECMO.\n\nSpecific aim 3: To evaluate the applicability of current guidelines for neurological prognostication after cardiac arrest in ECPR patients, and to assess the predictive value of individual and combined neurological tests in this specific patient population.\n\nSpecific aim 4: To determine the long-term neuropsychological outcomes, identify the problems survivors experience in daily life, and assess life satisfaction - by comprehensive follow-up visits with validated questionnaires and neuropsychology testing up to 12 years after the ECMO-treated cardiac arrest.",[99,100,28],"Cardiac Arrest","Extracorporeal Membrane Oxygenation","2026-01-14",{"date":103,"type":38},"2026-01-20",{"date":105,"type":38},"2010-01-01",{"date":107,"type":20},"2030-01-01",{"name":109,"class":45},"Sahlgrenska University Hospital",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":117,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":73},"100591747","cord-blood-s100b-protein-levels-in-neonates-following-intrauterine-transfusions-for-hdfn-associated-fetal-anemia-100591747","NCT06984445","Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia","Analysis of Cord Blood S100B Protein Levels in Neonates With Fetal Anemia Due to Hemolytic Disease Undergoing Intrauterine Transfusions: A Prospective Cohort Study","Study Group - Inclusion Criteria:\n\n1. Singleton pregnancy.\n2. Diagnosis of HDFN confirmed by the detection of alloantibodies through maternal blood screening.\n3. Availability of complete medical records, including routine ultrasound assessments of fetal MCA blood flow.\n4. Fetal anemia requiring IUT, indicated by a MCA-PSV MoM value exceeding 1.5.\n\nStudy Group - Exclusion Criteria:\n\n1\\. Maternal chronic use of selective serotonin reuptake inhibitors (SSRIs).\n\nControl Group - Inclusion Criteria:\n\n1. Singleton pregnancy.\n2. Diagnosis of HDFN confirmed by the detection of alloantibodies through maternal blood screening.\n3. Availability of complete medical records, including routine ultrasound assessments of fetal MCA blood flow.\n4. No indications for IUT, as determined by MCA-PSV MoM values \\\u003C1.5 in routine assessments of fetal cerebral arterial flow.\n\nControl Group - Exclusion Criteria:\n\n1\\. Maternal chronic use of selective serotonin reuptake inhibitors (SSRIs).","FEMALE","18 Years",{"count":120,"type":20},180,"levated levels of S100B protein are a well-established marker of central nervous system (CNS) damage. Fetal anemia resulting from hemolytic disease of the fetus and newborn (HDFN) often necessitates intrauterine transfusions (IUTs) and represents a significant risk factor for CNS injury. However, it remains uncertain whether S100B protein levels can reliably predict which fetuses are at higher risk for CNS complications in this context. Furthermore, the potential role of measuring S100B concentrations before IUT in prenatal assessments, and its relationship to the severity of anemia and fetal cerebral blood flow, remains poorly understood. This study aims to investigate the concentration of S100B protein in cord blood from newborns with HDFN-related fetal anemia requiring IUT. The study group comprises pregnancies complicated by HDFN with abnormal middle cerebral artery (MCA) blood flow, indicating the need for IUT. In this group, S100B protein levels will be measured before each IUT, with additional measurements if further transfusions are required. The control group consists of pregnancies with HDFN that do not require IUT. Cord blood samples will be collected at birth to evaluate S100B protein levels in both groups. Additionally, fetal MCA blood flow will be monitored, and in the study group, fetal hemoglobin and hematocrit levels will be assessed before each IUT. The primary endpoints of the study include the measurement of cord blood S100B protein levels before IUT in the study group and at birth in both groups. Secondary endpoints will explore the potential correlations between S100B protein levels and umbilical cord blood gas parameters (e.g., pH, BE, lactate), fetal cerebral blood flow parameters (e.g., MCA-PSV values), and blood count parameters (e.g., hemoglobin and hematocrit levels), both before IUT in the study group and after birth in both groups.",[123,28,124,125],"s100b","Hemolytic Disease of the Fetus and Newborn","Fetal Anemia",[127,128,129,130,131,132,133],"S100B protein","hemolytic disease of fetus and newborn (HDFN)","intrauterine transfusion (IUT)","fetal anemia","newborn","central nervous system (CNS) damage","CNS hypoxia-ischemia (HI)","2025-05-14",{"date":136,"type":38},"2025-05-22",{"date":138,"type":38},"2024-07-17",{"date":140,"type":20},"2026-04-30",{"name":142,"class":45},"Institute of Mother and Child, Warsaw, Poland",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":15,"minAge":118,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":73},"100504673","phase-2-burst-suppression-to-stop-refractory-status-epilepticus-post-cardiac-arrest-100504673","NCT05851391","buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest","buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)","RESTORE","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Non-traumatic, out-of-hospital cardiac arrest\n3. Comatose on admission - defined as not following commands\n4. Return of spontaneous circulation (ROSC) within less than 45 minutes\n5. Admission to the intensive care unit\n6. Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous\n\nEEG monitoring within 7 days from ROSC\n\nExclusion Criteria:\n\n1. Acute cerebral hemorrhage or infarction\n2. Pregnancy\n3. Prisoners",{"count":56,"type":20},[153],"PHASE2","RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.",[28,156,157,158,159,160,161],"Heart Arrest","Status Epilepticus","Refractory Status Epilepticus","Seizures","Anoxic-Ischemic Encephalopathy","Anoxia-Ischemia, Cerebral","2025-05-12",{"date":164,"type":38},"2025-05-15",{"date":166,"type":38},"2023-08-07",{"date":168,"type":20},"2027-04-30",{"name":170,"class":45},"University of California, San Francisco",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":117,"minAge":118,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":73},"100584789","cord-blood-s100b-protein-concentration-in-neonates-with-fetal-growth-restriction-100584789","NCT06893926","Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction","Evaluating the Utility of S100B Protein Concentration for Diagnosing Fetal Central Nervous System Hypoxia-Ischemia in Children With Late Fetal Growth Retardation: A Prospective Cohort Study","Study Group - Inclusion Criteria:\n\n1. Women with a full-term pregnancy (≥37 weeks of gestation), singleton.\n2. Pregnancy complicated by FGR.\n\nStudy Group - Exclusion Criteria:\n\n1. Antenatal (at recruitment):\n\n   * Maternal conditions that may affect the blood flow in placental vessels, including smoking, use of illicit stimulant substances, or pregestational diabetes.\n   * Maternal depression requiring pharmacological treatment (e.g., SSRIs).\n2. Intrapartum:\n\n   * Factors indicating a possible intrauterine infection, such as amniotic fluid leakage for more than 15 hours, spontaneous preterm labor, diagnosed intrauterine infection, or symptoms of infection in the mother.\n   * Prolonged labor lasting more than 15 hours.\n\nControl Group - Inclusion Criteria:\n\n1. Women with a full-term pregnancy (≥37 weeks of gestation), singleton.\n2. Pregnancy not complicated by FGR.\n\nControl Group - Exclusion Criteria:\n\n1. Antenatal (at recruitment):\n\n   * Maternal conditions that may affect placental blood flow, such as smoking, use of illicit stimulant substances, pregestational diabetes, or chronic hypertension.\n   * Maternal depression requiring pharmacological treatment (e.g., SSRIs).\n   * Risk factors for intrauterine HI, including abnormal fetal blood flow parameters on ultrasound, abnormal CTG recordings, or the need for intrauterine transfusion.\n2. Intrapartum:\n\n   * Indicators of possible intrauterine infection, such as amniotic fluid leakage for more than 15 hours, spontaneous preterm delivery, diagnosed intrauterine infection, or maternal symptoms of infection.\n   * Risk factors for perinatal HI.\n   * Prolonged labor lasting more than 15 hours (counted from the onset of regular uterine contractions).\n   * Birth weight below the 10th percentile or above the 90th percentile.\n   * Apgar score less than 8 at the 1st, 3rd, 5th, or 10th minute of life.\n   * Abnormal umbilical cord blood gas analysis results, defined as pH \\\u003C 7.15 or BE \\\u003C -9.3 mmol\u002Fl.\n3. Postnatal:\n\n   * Neonatal anemia requiring a top-up transfusion within the first 24 hours of life",{"count":179,"type":20},120,"S100B protein is a biomarker that increases following central nervous system (CNS) damage. Measuring this protein's levels may allow for the early identification of infants at high risk for developmental abnormalities, such as fetal growth restriction (FGR), even on the first day of life, in a non-invasive manner. Early detection could enable timely interventions and rehabilitation, potentially improving the child's prognosis and long-term outcomes. This study investigates two groups of full-term pregnancies: a study group with prenatally diagnosed late FGR, and a control group with normal fetal growth. Following delivery, cord blood samples from both groups will be analyzed for S100B protein concentrations, pH, base excess (BE), and lactate levels. Additionally, fetal blood flow parameters in the umbilical artery (UA), uterine arteries (UtA), ductus venosus (DV), and middle cerebral artery (MCA) will be monitored via ultrasound within 48 hours before delivery. This study aims to compare S100B protein concentrations in umbilical cord blood between the two groups and to assess correlations with fetal Doppler parameters, pH, BE, and lactate levels in cord blood gas analysis. Ultimately, we seek to determine the effectiveness of S100B protein concentration as a biomarker for diagnosing fetal CNS hypoxia- ischemia in FGR-affected children, compared to those with normal growth.",[123,28,182],"Fetal Growth Restriction (FGR)",[127,184,131,132,133],"fetal growth restriction (FGR)","2025-03-24",{"date":187,"type":38},"2025-03-25",{"date":189,"type":38},"2024-06-18",{"date":191,"type":20},"2026-03-31",{"name":142,"class":45},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":15,"minAge":118,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":218},"100519841","early-cessation-of-sedation-and-ttm-in-patients-with-a-favourable-eeg-after-cardiac-arrest-100519841","NCT06048796","Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest","Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest: a Feasibility and Safety Study","SELECT","Inclusion Criteria:\n\n* Patients after cardiac arrest admitted to the ICU for treatment with sedation, TTM and mechanical ventilation.\n* Age 18 years or older.\n* Continuous EEG measurement started within 12 hours after cardiac arrest.\n* Favourable EEG pattern within 12 hours after arrest, defined as a continuous background pattern (NVN, 2019; Ruijter et al., 2019).\n* Possibility to stop sedative treatment within three hours after identification of a favourable EEG pattern.\n* Written informed consent (deferred).\n\nExclusion Criteria:\n\n* A known history of another medical condition with limited life expectancy (\\\u003C6 months).\n* Any progressive brain illness, such as a brain tumour or neurodegenerative disease.\n* Pre-admission Glasgow Outcome Scale Extended score of 4 or lower.\n* Reason other than neurological condition to continue sedation and\u002For ventilation.\n* Follow-up impossible due to logistic reasons.",{"count":202,"type":20},40,[23],"The objective of this study is to estimate the feasibility and safety of early weaning from ICU treatment in patients after cardiac arrest and an early (\\\u003C 12 h) favourable EEG pattern (indicating no or mild postanoxic encephalopathy).",[28,156],[207,208],"EEG","targeted temperature management (TTM)","2024-05-10",{"date":211,"type":38},"2024-05-13",{"date":213,"type":38},"2024-03-12",{"date":215,"type":20},"2026-10",{"name":217,"class":45},"Medisch Spectrum Twente",2]